Rockwell Medical, Inc.
Rockwell Medical operates as a healthcare company developing hemodialysis products. The company manufactures and distributes various concentrates for dialysis providers worldwide. Products include CitraPure, Dri-Sate, RenalPure, and SteriLyte concentrates, as well as ancillary supplies. Hemodialysis concentrates sustain patients lives by removing toxins and balancing electrolytes. The company serves hemodialysis clinics. Rockwell Medical was formerly known as Rockwell Medical Technologies, Inc. before changing its name in 2012.
Overview
Strengths
- Price to book ratio (0.96) is lower than the sector mean (733.70).
- The company has low debt. Net Debt to EBITDA Ratio is 0.72 and it is lower than the sector mean.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data